Skip Navigation
ChemIDplus A TOXNET DATABASE Lite•Browse•Advanced

Substance Name: Ketorolac tromethamine [USAN:USP]
RN: 74103-07-4
UNII: 4EVE5946BQ
InChIKey: BWHLPLXXIDYSNW-UHFFFAOYSA-N

Note

  • A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.

Molecular Formula

  • C15-H13-N-O3.C4-H11-N-O3

Molecular Weight

  • 376.4066
 

Classification Codes

  • Analgesic
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antirheumatic Agents
  • Cyclooxygenase Inhibitors
  • Drug / Therapeutic Agent
  • Enzyme Inhibitors
  • Human Data
  • Peripheral Nervous System Agents
  • Sensory System Agents

Names and Synonyms

Name of Substance

  • Ketorolac tromethamine
  • Ketorolac tromethamine [USAN:USP]

MeSH Heading

  • Ketorolac tromethamine

Synonyms

  • (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
  • Acular
  • Acular LS
  • Acular PF
  • Acular preservative free
  • Acuvail
  • Godek
  • Ketorolac tromethamine
  • Ketorolac tromethamine ophthalmic solution
  • Sprix
  • Syntex
  • Toradol
  • Tromethamine ketorolac
  • UNII-4EVE5946BQ

Systematic Name

  • 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)

Registry Numbers

CAS Registry Number

  • 74103-07-4

FDA UNII

  • 4EVE5946BQ

System Generated Number

  • 0074103074

Molecular Formulas

Molecular Formula

  • C15-H13-N-O3.C4-H11-N-O3

Molecular Formula Fragments

  • C15-H13-N-O3
  • C4-H11-N-O3
  • COMPONENT

Structure Descriptors

InChI

1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

InChIKey

BWHLPLXXIDYSNW-UHFFFAOYSA-N

Smiles

c1ccc(cc1)C(=O)c2ccc3n2CCC3C(=O)O.C(C(CO)(CO)N)O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo intramuscular 857ug/kg (0.857mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP		 Journal of Toxicology, Clinical Toxicology. Vol. 32, Pg. 305, 1994.
man TDLo intramuscular 858ug/kg (0.858mg/kg)   Annals of Pharmacotherpy. Vol. 26, Pg. 1237, 1992.
man TDLo intramuscular 858ug/kg (0.858mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP		 Annals of Pharmacotherpy. Vol. 26, Pg. 1237, 1992.
man TDLo intramuscular 4300ug/kg/8D- (4.3mg/kg) BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"

KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"		 Clinical Nephrology. Vol. 44, Pg. 276, 1995.
man TDLo intramuscular 19853ug/kg/12 (19.853mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" Annals of Pharmacotherpy. Vol. 27, Pg. 1055, 1993.
mouse LD50 intraperitoneal 225mg/kg (225mg/kg) SKIN AND APPENDAGES (SKIN): HAIR: OTHER

BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)		 Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999.
mouse LD50 oral 293mg/kg (293mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA

SKIN AND APPENDAGES (SKIN): HAIR: OTHER		 Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999.
rat LD50 oral 189mg/kg (189mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

SKIN AND APPENDAGES (SKIN): HAIR: OTHER		 Toksikologicheskii Vestnik. Vol. (6), Pg. 41, 1999.
women LDLo intramuscular 15mg/kg/6D-I (15mg/kg)   Archives of Internal Medicine. Vol. 153, Pg. 1000, 1993.
women LDLo intramuscular 15mg/kg/6D-I (15mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" Archives of Internal Medicine. Vol. 153, Pg. 1000, 1993.
women TDLo intramuscular 600ug/kg (0.6mg/kg) GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF ENDOCRINE PANCREAS Archives of Internal Medicine. Vol. 158, Pg. 411, 1998.
women TDLo intramuscular 1200ug/kg (1.2mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

LUNGS, THORAX, OR RESPIRATION: BRONCHIOLAR CONSTRICTION

BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"		 Southern Medical Journal. Vol. 87, Pg. 282, 1994.
women TDLo intramuscular 8400ug/kg/3D- (8.4mg/kg)   American Journal of Kidney Diseases. Vol. 24, Pg. 578, 1994.
women TDLo intramuscular 8400ug/kg/3D- (8.4mg/kg) KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" American Journal of Kidney Diseases. Vol. 24, Pg. 578, 1994.

Physical Properties

Physical Property Value Units Temp (deg C) Source
log P (octanol-water) -0.59 (none)   EXP
Water Solubility 1.37E+04 mg/L 25 EST
Vapor Pressure 2.64E-21 mm Hg 25 EST
Henry's Law Constant 3.34E-28 atm-m3/mole 25 EST
Atmospheric OH Rate Constant 2.15E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.